Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 262

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 262
---
                                                 |     | $            |     (8.84 | ) |     | $            |     (0.52 | ) |     | $           |       0.28 |   |
| Weighted average outstanding shares (basic and diluted)                 |     |              | 1,048,632 |   |     |              | 4,193,689 |   |     |             | 26,746,852 |   |
| Weighted average loss per share (basic and diluted)                     |     | $            |     (1.94 | ) |     | $            |     (0.03 | ) |     | $           |      (0.11 | ) |

____________ (1)Book value per share is calculated using the formula: total shareholders’ equity from the balance sheet as of June 30, 2024 divided by shares outstanding as of June 30, 2024. (2)The pro forma combined numbers include the adjustments according to Kadimastem’s and NLS’s Unaudited Pro Forma Condensed Combined Balance Sheets as presented in this proxy statement/prospectus on page 191.

131 NLS BUSINESS NLS is a clinical -stagebiopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex CNS disorders with unmet medical needs. NLS’s lead compound mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary extended -release, or ER formulation, is being developed for the treatment of narcolepsy (lead indication) and ADHD (follow -onindication). NLS believes that this dual mechanism of action will also enable mazindol ER to provide potential therapeutic benefit in other rare and complex CNS disorders. CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders. However, treatment options for these conditions are often limited, inadequate or nonexistent, and the development of new CNS treatments generally trails behind other therapeutic areas. NLS is pursuing the development of the next generation of CNS therapies with high medical impact to address this critical and growing unmet need. NLS’s dual development strategy is designed to optimize the outcome of its clinical programs by developing new chemical entities from known molecules with strong scientific rationale, and also by re -definingpreviously approved molecules with well -establishedtolerability and safety profiles, as determined by applicable regulatory agencies. NLS believes that its streamlined clinical development approach